The cost of drug development: a systematic review

Morgan, S and Grootendorst, P and Lexchin, J and Cunningham, C (2011) The cost of drug development: a systematic review. Health Policy, 100 (1). pp. 4-17. ISSN 0168-8510

Full text not available from this repository.
Official URL: http://www.sciencedirect.com/science/article/pii/S...

Abstract

Objectives We aimed to systematically review and assess published estimates of the cost of developing new drugs. Methods We sought English language research articles containing original estimates of the cost of drug development that were published from 1980 to 2009, inclusive. We searched seven databases and used citation tracing and expert referral to identify studies. We abstracted qualifying studies for information about methods, data sources, study samples, and key results. Results Thirteen articles were found to meet our inclusion criteria. Estimates of the cost of drug development ranged more than 9-fold, from USD$92 million cash (USD$161 million capitalized) to USD$883.6 million cash (USD$1.8 billion capitalized). Differences in methods, data sources, and time periods explain some of the variation in estimates. Lack of transparency limits many studies. Confidential information provided by unnamed companies about unspecified products forms all or part of the data underlying 10 of the 13 studies. Conclusions Despite three decades of research in this area, no published estimate of the cost of developing a drug can be considered a gold standard. Studies on this topic should be subjected to reasonable audit and disclosure of – at the very least – the drugs which authors purport to provide development cost estimates for.

Item Type: Article
Subjects: R > Research and development
P > Pharmaceutical industry
Subject Areas: Strategy and Entrepreneurship
DOI: 10.1016/j.healthpol.2010.12.002
Date Deposited: 31 Aug 2017 15:19
Last Modified: 31 Aug 2017 15:19
URI: http://lbsresearch.london.edu/id/eprint/874

Actions (login required)

Edit Item Edit Item